Hormone APIs are my country's traditional export commodities with high market concentration. However, in recent years, due to the impact of the European debt crisis and rising domestic factor costs, its exports have been hovering at a low level. In 2014, the average export price fell by 17.97%, which was the lowest ever.

According to China Customs statistics, in 2014, my country's hormone-based API exports increased by 52.99% year-on-year, achieving the largest increase since the European debt crisis. It can be seen that with the continuous recovery of the main European economies, my country's hormone-based API exports have stepped forward. Enter the normal trade track.

In recent years, due to the increase in domestic clinical applications and the development of the breeding industry, the output of hormone-based APIs has increased year by year, and the industry has developed rapidly. I believe that with the continuous advancement of my country's pharmaceutical technology, hormone-based APIs will have more development prospects.

Volume and price part ways

In 2014, the export volume of hormone-based APIs in my country increased by 86.5% year-on-year, while the average export price fell by 17.97% year-on-year. Therefore, the analysis believes that although the European economic recovery has brought benefits to my country's pharmaceutical export trade, the capital chain of foreign buyers is still tense , So that the profits of my country's export enterprises are squeezed.

In 2014, my country's hormone-based APIs were exported to 112 countries and regions, of which: exports to Asia increased by 46.43% year-on-year; exports to Europe increased by 78.67% year-on-year. The above-mentioned two continents are the main export markets of my country's hormone APIs, accounting for 80.12%. In 2014, my country's top 10 export trading partners were India, the United States, Italy, the Netherlands, Belgium, Germany, Switzerland, the United Kingdom, Spain, and Brazil. 10 countries accounted for 71.24% of my country's total export of hormone APIs.

 In 2014, there were 510 companies engaged in the export of hormone-based APIs in my country. Among them, there are 393 private enterprises, accounting for 47.7% of the export value, accounting for about half of my country's hormone API exports, and 49 foreign-funded enterprises, accounting for 24.91% of the export value. Tianjin Tianfa Pharmaceutical Import and Export Company, Changzhou Jiaerke Pharmaceutical, Zhejiang Xianju Pharmaceutical, Zhejiang Xianju Junye Pharmaceutical, Tiantai County Ao Ruite Pharmaceutical, Henan Lihua Pharmaceutical, Hunan Steroid Chemicals The company, Zhejiang Xianju Xianle Pharmaceutical Co., Ltd., Jiangxi Hongyuan Pharmaceutical Raw Material Co., Ltd., and Tianjin Jinjin Pharmaceutical Co., Ltd. occupy the top 10 of my country's hormone API export companies. Zhejiang, Tianjin, and Jiangsu rank among the top three export provinces and cities, accounting for 62.09% of the export value, reflecting the extremely high market concentration.

 The status of a major exporter continues

Hormone drugs in a broad sense are drugs that use human or animal hormones (including organic substances with the same structure and action principle as hormones) as their active ingredients. Generally, the term "hormonal drugs" used by doctors generally refers to adrenal glucocorticoid drugs when there is no special designation. Other hormonal drugs are commonly used by their classification names, such as androgen, insulin, growth hormone, etc.

In 2014, the top 10 export varieties of hormone APIs in China were: other estrogen and progesterone; cortisone, hydrocortisone, dehydrocortisone and dehydrocortisol; other cortex Halogenated derivatives of steroid hormones; other steroid hormones and their derivatives and structural analogs; dexamethasone; sex agonists; danazol; dehydrochloromethyltestosterone (including andros-1-ene-3,17 -Diketone, (Δ)androstenediol, prasterone, deoxymethyltestosterone); mibodone, nandrolone, nobolone, norstib (including 19-norandrostenediol, 19 -Norandrostenedione, norethandrolone); other hormones and their derivatives and structural analogs.

Hydrocortisone and dexamethasone are still the bulk varieties of my country's hormone raw materials exports, accounting for about 30% of the export value. In 2014, the export volume and price of hydrocortisone decreased by 5.57% and 8.04% respectively; the main exports were The markets are: Asia, Europe and North America, with export value accounting for 88.82%. Among the exporting countries, India, Italy, the United States, Spain, and Germany rank the top 5, with export value accounting for 53.72%.

The top 5 export companies are Tianjin Tianfa Pharmaceutical, Henan Lihua Pharmaceutical, Zhejiang Xianju Pharmaceutical, Tianjin Jinjin Pharmaceutical, and Lijiang Yinghua Biology, with an export value of 79.97%. Diene, epoxy progesterone, 16-DPA

The export volume of dexamethasone increased by 9.37%, and the export price fell by 6.43%; the export value of Africa and Latin America, which are emerging markets, increased by 67.58% and 31.12%, respectively, becoming a highlight of dexamethasone exports in 2014. The top 5 export countries are all Asian markets, namely India, Indonesia, Malaysia, Singapore, and Pakistan, with export value accounting for 59.07%.

 The top 5 export companies are Tianjin Tianfa Pharmaceutical, Zhejiang Xianju Pharmaceutical, Zhejiang Xianju Junye Pharmaceutical, Zhejiang Xianju Xianle Pharmaceutical, and Hengshi Group, with export value accounting for 89.11%.

my country is a major exporter of hormone-based APIs and has a leading position in the international market. It is predicted that in 2015, the weak economic situation of Europe and Japan in the international markets will be difficult to change in the short term. The performance of emerging markets and small and medium-sized emerging economies is generally poor. The decline in commodity prices will inevitably lead to weak market demand and tightening global liquidity, making the world The trend of economic differentiation is obvious.

Domestically, the downward pressure on the overall economy has increased. The reduction in the planting area of the upstream raw material yellow ginger and the increase in environmental protection requirements have caused costs to rise. All these unfavorable factors have cast a shadow on the recovery and growth of our hormone API exports. Companies rely on traditional models to sell abroad. The possibility of market profitability is no longer large. Therefore, my country’s hormone-based API business companies must change their traditional marketing model, accelerate industrial transformation, shift from low-price competition to quality and technology competition, increase the development of high-end products, break down the competitive pressure of low-end products, and create their own Brand-name products, strive for more international market shares, improve the export efficiency of my country's hormone API products, and promote the balanced development of industry supply and demand.